z-338 and Helicobacter-Infections

Functional dyspepsia (FD) is a relatively common gastrointestinal clinical condition that remains poorly understood. Controversies remain regarding the definition, pathophysiology and optimum treatment. The current treatment of FD is limited and no established regimen is available.. Recent advances have improved our understanding of the pathophysiology of the disease and have led to the development of newer tailored therapies. Novel agents such as the motilin receptor agonist camicinal and the muscarinic M1 and M2 receptor antagonist acotiamide appear promising; however, the need for a safe and efficacious treatment remains largely unmet. This review describes the currently available management options for FD and critically evaluates emerging therapies.. The optimal treatment for FD is yet to be determined. A proton pump inhibitor or a prokinetic agent constitutes primary treatment. Helicobacter pylori testing and eradication is recommended. Based on currently available data, acotiamide appears promising, particularly in postprandial distress syndrome. Further large-scale multicentered trials are required to define the duration of treatment and the side-effect profile.

Topics: Benzamides; Drug Design; Dyspepsia; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Postprandial Period; Proton Pump Inhibitors; Thiazoles

Topics: Benzamides; Diet; Disease Management; Dyspepsia; Helicobacter Infections; Humans; Life Style; Psychology; Thiazoles